MDT-AP-2074
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 4
- sex
- M
- new_clusters
- C3
- umap1_2d
- 6.066200247
- umap2_2d
- 2.711198788
- umap1_3d
- 2.168393207
- umap2_3d
- -1.174946952
- umap3_3d
- -0.878203155
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.430
- OXIDATIVE_PHOSPHORYLATION+0.280
- SPERMATOGENESIS+0.280
- DNA_REPAIR+0.220
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.150
- KRAS_SIGNALING_DN+0.140
- XENOBIOTIC_METABOLISM+0.120
- ADIPOGENESIS+0.110
- ESTROGEN_RESPONSE_LATE+0.110
- FATTY_ACID_METABOLISM+0.060
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.480
- ANGIOGENESIS-0.410
- TGF_BETA_SIGNALING-0.380
- MYC_TARGETS_V2-0.360
- UV_RESPONSE_DN-0.360
- MITOTIC_SPINDLE-0.340
- WNT_BETA_CATENIN_SIGNALING-0.340
- NOTCH_SIGNALING-0.330
- INFLAMMATORY_RESPONSE-0.320
- KRAS_SIGNALING_UP-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2615 | Med | Medulloblastoma | 0.919 |
| 2 | MDT-AP-0563 | Med | Medulloblastoma | 0.884 |
| 3 | MDT-AP-1302 | Med | Medulloblastoma | 0.865 |
| 4 | MDT-AP-0349 | Med | Medulloblastoma | 0.864 |
| 5 | TCGA-XF-A8HC-01A-11R-A36F-07 | — | — | 0.859 |
| 6 | BS_9DZ253JY | pilocytic astrocytoma | — | 0.845 |
| 7 | SRR33532828 | — | B | 0.843 |
| 8 | TCGA-UP-A6WW-01A-12R-A34R-07 | — | — | 0.840 |
| 9 | SRR1387199 | GTEX | — | 0.836 |
| 10 | SRR934734 | — | — | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.430 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.280 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.010 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.010 | Inavolisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |